Abstract:The role of BRCA2 gene somatic mutations are mainly to maintain genome integrity in response to DNA damage through different mechanisms. Deregulation of BRCA2 is associated with the development of tumor and altered sensitivity to chemotherapeutic agents, but the genetic variability of BRCA2 somatic mutation NSCLC patients is unclear. The aim of this study is to investigate mutations and prognosis of NSCLC harboring BRCA2 somatic mutations. A total of 362 patients with non-small-cell lung cancer were recruited between July 2012 and December 2015. The status of BRCA2 somatic mutation and other genes were detected by next generation sequencing. BRCA2 gene somatic mutation rate was 4.97% (18/362) in non-small cell lung cancer, including S547P (2 patients), G1433W (2 patients), I488V (1 patient), C315S (1 patient), T2007S (1 patient), I1929V (1 patient), H3117Y (1 patient), G1370V (1 patient), T768S (1 patient), E2260Q (1 patient), R2087K (1 patient), E3167Q (1 patient), S163T (1 patient), T152I (1 patient), E2275Q (1 patient) and S163T (1 patient) , and median overall survival (OS) for these patients was 18.0 months. Among them, all patients were BRCA2 gene with co-occurring somatic mutation. Briefly, patients with (n=3) or without (n=15) co-occurring EGFR mutations had a median OS of 21.0 months and 18.0 months respectively (P=0.22); patients with (n=11) or without (n=7) co-occurring TP53 mutations had a median OS of 7.5 months and 18.0 months respectively (P=0.15); patients with (n=2) or without (n=16) co-occurring HER2 mutations had a median OS of 11.0 months and 20.0 months respectively (P=0.24). BRCA2 mutations represent a distinct subset of NSCLC. NGS might be useful for evaluation of BRCA2 unclassified variants. Our results show that BRCA2 mutations delineate an aggressive subtype of lung cancer for which a targeted treatment through BRCA2 inhibition might offer new opportunities.

P1.03-27 Somatic Mutations in BRCA2 Genes Are Associated with Prognosis in Chinese Non-Small-Cell Lung Cancer Patients